BioSpace News Archive

Omeros Corporation (Nasdaq: OMER): The results of Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the virtual edition of the 25th annual European Hematology Association Congress. The presentation, entitled Narsoplimab (OMS721) for the Treatment of Adult Hematopoietic Stem Cell Transplant-A

Next Generation Closed Loop Insulin Pump System Features Auto-Correction Algorithm and Bluetooth Connectivity

Bio-Techne Corporation announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of Prostate Cancer, the leading national nonprofit organization in the fight against prostate cancer.

Regeneron Pharmaceuticals, Inc. announced initiation of the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19.

FINANCING WILL ADVANCE BARDOXOLONE AS THE FIRST POTENTIAL THERAPY FOR ALPORT SYNDROME, AS WELL AS CONTINUE DEVELOPMENT FOR OTHER RARE AND SERIOUS FORMS OF CHRONIC KIDNEY DISEASE REATA’S CASH GUIDANCE UPDATED: RUNWAY EXTENDED THROUGH END OF 2023 REATA TO HOST CONFERENCE CALL ON JUNE 11, 2020 AT 8:30 AM ET NEW YORK and PLANO, Texas, June 11, 2020 (GLOBE NEWSWIRE) -- Blackstone (NYSE: BX) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata”), a clinical-stage biopharmaceutical co

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST,

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari , PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Forum on

Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announced today a corporate strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal of validating novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop poten

Nanotronics today announced that it has developed and designed nHale™, a bi-level positive air pressure (BIPAP) device to support spontaneously breathing adults weighing over 30 kg.

CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its lead product Berubicin for the treatment of malignant gliomas